Experimental cell therapy offers hope for kids with rare COVID-Linked syndrome
Disease control
NO_LONGER_AVAILABLE
This study provided early access to an experimental treatment called remestemcel-L for children aged 2 months to 17 years with MIS-C, a severe inflammatory condition linked to COVID-19. The goal was to see if the therapy could safely reduce inflammation and improve outcomes. The …
Sponsor: Mesoblast International Sàrl • Aim: Disease control
Last updated May 13, 2026 16:01 UTC